Jagiellonian University Repository

Recent development of multifunctional agents as potential drug candidates for the treatment of Alzheimer's disease


Recent development of multifunctional agents as potential drug candidates for the treatment of Alzheimer's disease

Show full item record

dc.contributor.author Szałaj, Natalia [SAP20012177] pl
dc.contributor.author Więckowska, Anna [SAP20002544] pl
dc.contributor.author Panek, Dawid [SAP20015004] pl
dc.contributor.author Malawska, Barbara [SAP20000689] pl
dc.date.accessioned 2020-01-17T08:46:06Z
dc.date.available 2020-01-17T08:46:06Z
dc.date.issued 2015 pl
dc.identifier.issn 0929-8673 pl
dc.identifier.uri https://ruj.uj.edu.pl/xmlui/handle/item/134650
dc.language eng pl
dc.rights Udzielam licencji. Uznanie autorstwa 4.0 Międzynarodowa *
dc.rights.uri http://creativecommons.org/licenses/by/4.0/pl/legalcode *
dc.title Recent development of multifunctional agents as potential drug candidates for the treatment of Alzheimer's disease pl
dc.type JournalArticle pl
dc.description.physical 373-404 pl
dc.description.additional Na pub. aut. podpis.: Natalia Guzior pl
dc.abstract.en Alzheimer’s disease (AD) is a complex and progressive neurodegenerative disorder. The available therapy is limited to the symptomatic treatment and its efficacy remains unsatisfactory. In view of the prevalence and expected increase in the incidence of AD, the development of an effective therapy is crucial for public health. Due to the multifactorial aetiology of this disease, the multi-target-directed ligand (MTDL) approach is a promising method in search for new drugs for AD. This review updates information on the development of multifunctional potential anti-AD agents published within the last three years. The majority of the recently reported structures are acetylcholinesterase inhibitors, often endowed with some additional properties. These properties enrich the pharmacological profile of the compounds giving hope for not only symptomatic but also causal treatment of the disease. Among these advantageous properties, the most often reported are an amyloid- antiaggregation activity, inhibition of -secretase and monoamine oxidase, an antioxidant and metal chelating activity, NOreleasing ability and interaction with cannabinoid, NMDA or histamine H3 receptors. The majority of novel molecules possess heterodimeric structures, able to interact with multiple targets by combining different pharmacophores, original or derived from natural products or existing therapeutics (tacrine, donepezil, galantamine, memantine). Among the described compounds, several seem to be promising drug candidates, while others may serve as a valuable inspiration in the search for new effective therapies for AD. pl
dc.subject.en Alzheimer’s disease pl
dc.subject.en antioxidants pl
dc.subject.en β-amyloid anti-aggregation properties pl
dc.subject.en cholinesterase inhibitors pl
dc.subject.en inhibitors of β-secretase pl
dc.subject.en inhibitors of monoamine oxidase A/B pl
dc.subject.en multi-target-directed ligands pl
dc.subject.en neuroprotective properties pl
dc.description.volume 22 pl
dc.description.number 3 pl
dc.description.points 40 pl
dc.identifier.doi 10.2174/0929867321666141106122628 pl
dc.identifier.eissn 1875-533X pl
dc.title.journal Current Medicinal Chemistry pl
dc.language.container eng pl
dc.affiliation Wydział Farmaceutyczny : Zakład Fizykochemicznej Analizy Leku pl
dc.subtype Article pl
dc.rights.original CC-BY; inne; ostateczna wersja wydawcy; w momencie opublikowania; 0 pl
dc.identifier.project ROD UJ / OP pl
dc.cm.id 69737
dc.cm.date 2020-01-07
.pointsMNiSW [2015 A]: 40

Files in this item

This item appears in the following Collection(s)

Udzielam licencji. Uznanie autorstwa 4.0 Międzynarodowa Except where otherwise noted, this item's license is described as Udzielam licencji. Uznanie autorstwa 4.0 Międzynarodowa